Compare Alcon AG (ALC) vs Fabrinet (FN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Fabrinet — how do they compare? Alcon AG trades at $74.19 (market cap $36.44B), while Fabrinet trades at $545.91 (market cap $18.84B). The key difference: Alcon AG is the larger of the two by market cap, and Alcon AG pays a 0.48% dividend while Fabrinet pays none. Which is the better fit depends on your goals.
| ALC | FN | |
|---|---|---|
Market Cap | $36.44B | $18.84B |
Sector | Health | Technology |
52-Week High | $90.12 | $746.47 |
52-Week Low | $62.02 | $277.04 |
Enterprise Value | $40.28B | $17.90B |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Fabrinet (FN) trades at $562.38, up 3.39% in 24 hours, near its 52-week high of $748.89. The stock shows bullish technical signals with strong moving average support and a neutral RSI. Recent earnings beats in Q3 2025 to Q1 2026 highlight robust growth, with Q2 2026 EPS expected at $3.81. Revenue grew to $3.42B in 2025, with net income at $332.53M, though valuation ratios like P/E of 45.28 appear elevated.
Outlook remains positive driven by AI infrastructure demand, with analysts projecting 75% buy ratings. Key risks include premium valuation sensitivity and supply chain constraints. The stock offers growth exposure but requires monitoring of execution and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →
